NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 2 November 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Chair Topic 1 & 3) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1 to 4.2.2 & 6 to 6.2.2
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Chris Herring Present for all items
8. Dr Andrew Hitchings Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Dr Ivan Koychev Present for all items
12. Dr Soo Fon Lim Present for all items
13. Dr Guy Makin Present for all items
14. Dr Philip Mallender Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Dr Rebecca Payne Present for all items
18. Carole Pitkeathley Present for all items
19. Dr Raju Reddy Present for all items
20. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Elizabeth Bell, Heath Technology Assessment Adviser Items 1 to 4.2.2

Fatima Chunara, Heath Technology Assessment Adviser Items 5 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 6 to 6.2.2

Summaya Mohammed, Heath Technology Assessment Analyst Items 1 to 4.2.2

Owen Swales, Heath Technology Assessment Analyst Items 5 to 5.2.2

Janet Boadu, Heath Technology Assessment Analyst Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 5.2.2

Ruth Melville, Senior Medical Editor Items 5 to 5.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Rosalee Mason, Coordinator, Corporate Office Items 1 to 4.1.3 & 6 to 6.1.3

Lyn Davis, Coordinator, Corporate Office Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Ayla Hudson, Apprentice, COT Items 5 to 5.2.2

NICE staff (observers) present

Caron Jones, Heath Technology Assessment Adviser Items 1 to 4.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 1 to 4.2.2

Liam Murray, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

External assessment group representatives present

Katy Cooper, School of Health, and Related Research (ScHARR), Items 1 to 4.1.3

Paul Tappenden, School of Health, and Related Research (ScHARR), Items 1 to 4.1.3

Caroline Farmer, Peninsula Technology Assessment Group (Pen-TAG), Items 5 to 5.1.3

Simone Critchlow, Peninsula Technology Assessment Group (Pen-TAG), Items 5 to 5.1.3

Mariana Bacelar, BMJ Group Items 6 to 6.1.3

Charlotta Karner, BMJ Group Items 6 to 6.1.3

Clinical, patient & NHS England experts present

Dr Charlotte Benson, Consultant Medical Oncologist, Clinical expert nominated by GIST Cancer UK, Items 1 to 4.1.3

Dr Ramesh Belusu, Consultant Oncologist and Network GIST Lead, Clinical expert nominated by GIST Cancer UK, Items 1 to 4.1.3

Bradley Price, Patient expert, nominated by Sarcoma UK, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drugs Fund Clinical Lead, NHS England, Items 1 to 4.2.2

Professor Alan Salama, Professor of Nephrology, Clinical expert nominated by LUPUS UK, Items 5 to 5.1.3

Amy Somers, Patient expert, nominated by LUPUS UK, Items 5 to 5.1.3

Sian Brennan, Client Director – Business Consultancy, Patient expert nominated by LUPUS UK, Items 5 to 5.1.3

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 5 to 5.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Stephen Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 5 October 2022

### Appraisal of ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Deciphera Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Giles Monnickendam, Dr Rebecca Payne, and Carole Pitkeathley
  1. Part 2 – Closed session (company representatives, clinical & patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10671>

### Appraisal of voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, and company representatives from Otsuka Pharmaceuticals.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared that he has conducted consultancy work for Otsuka in an unrelated area. The funding went to the University of Leeds and personally to him. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Matt Bradley has declared that he is employed by GSK the manufacturer of belimumab. Although this medicine hasn't been reviewed by NICE, it is licensed for use in Lupus Nephritis. This has been considered and it was agreed that this is a conflict and would prevent Dr Bradley from participating in discussions on this appraisal.
* Patient expert Amy Somers declared that she is the Lupus Europe admin assistant (from December 2019 to September 2021) and is a trustee of Lupus Europe and Lupus Europe PAN (patient advisory network) member working with pharma and academic research from 2018 onwards, as well as a Lupus UK northwest committee member from 2019 onwards. Amy also declared that she is on the Global Lupus patient panel for Roche, a patient advisor for Boehringer Ingelheim and a EUPATI fellow. It was agreed her declarations would not prevent Amy from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Christopher Herring, Dr Robert Hodgson, and Carole Pitkeathley
  1. Part 2 – Closed session (company representatives, clinical and experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10878>

### Appraisal of maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

* 1. Part 1 – Open session
     1. The chair Dr Stephen Smith welcomed, external assessment group representatives, and company representatives from Takeda UK.
     2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from Takeda for research in a related area. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10792>

The next meeting of the Technology Appraisal Committee D will be held on **Wednesday 7 December** and will start promptly at 09.30.